These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Langer T; Krovat EM Curr Opin Drug Discov Devel; 2003 May; 6(3):370-6. PubMed ID: 12833670 [TBL] [Abstract][Full Text] [Related]
25. Virtual screening strategies in drug discovery. McInnes C Curr Opin Chem Biol; 2007 Oct; 11(5):494-502. PubMed ID: 17936059 [TBL] [Abstract][Full Text] [Related]
26. From targets to leads: the importance of advanced data analysis for decision support in drug discovery. Fischer HP; Heyse S Curr Opin Drug Discov Devel; 2005 May; 8(3):334-46. PubMed ID: 15892249 [TBL] [Abstract][Full Text] [Related]
27. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Crivori P; Poggesi I Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065 [TBL] [Abstract][Full Text] [Related]
28. Fragment analysis in small molecule discovery. Merlot C; Domine D; Church DJ Curr Opin Drug Discov Devel; 2002 May; 5(3):391-9. PubMed ID: 12058614 [TBL] [Abstract][Full Text] [Related]
29. High-content screening: a new primary screening tool? Bickle M IDrugs; 2008 Nov; 11(11):822-6. PubMed ID: 18988127 [TBL] [Abstract][Full Text] [Related]
30. Virtual screening in lead discovery and optimization. Jain AN Curr Opin Drug Discov Devel; 2004 Jul; 7(4):396-403. PubMed ID: 15338948 [TBL] [Abstract][Full Text] [Related]
31. High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. Posner BA Curr Opin Drug Discov Devel; 2005 Jul; 8(4):487-94. PubMed ID: 16022185 [TBL] [Abstract][Full Text] [Related]
33. HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Netzer R; Bischoff U; Ebneth A Curr Opin Drug Discov Devel; 2003 Jul; 6(4):462-9. PubMed ID: 12951809 [TBL] [Abstract][Full Text] [Related]
34. Fragment-based lead discovery: a chemical update. Erlanson DA Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612 [TBL] [Abstract][Full Text] [Related]
36. Pharmaceutical industry screening for new antiepileptic drugs. Taylor CP; Marks JL Adv Neurol; 1998; 76():41-7. PubMed ID: 9408462 [TBL] [Abstract][Full Text] [Related]
37. Strategies for conducting ADME studies during lead generation in the drug discovery process. Cramer JW; Mattioni BE; Savin KA IDrugs; 2010 Dec; 13(12):857-61. PubMed ID: 21154143 [TBL] [Abstract][Full Text] [Related]
38. Dissimilarity-based approaches to compound acquisition. Lajiness M; Watson I Curr Opin Chem Biol; 2008 Jun; 12(3):366-71. PubMed ID: 18423415 [TBL] [Abstract][Full Text] [Related]
40. In silico pharmacology for a multidisciplinary drug discovery process. Ortega SS; Cara LC; Salvador MK Drug Metabol Drug Interact; 2012; 27(4):199-207. PubMed ID: 23152402 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]